Erekaha Salome C, Cornelius Llewellyn J, Bessaha Melissa L, Ibrahim Abdulmumin, Adeyemo Gabriel D, Fadare Mofoluwake, Charurat Manhattan, Ezeanolue Echezona E, Sam-Agudu Nadia A
a International Research Center of Excellence, Institute of Human Virology Nigeria , Abuja , Nigeria.
b School of Social Work and College of Public Health, University of Georgia Athens , USA.
SAHARA J. 2018 Dec;15(1):128-137. doi: 10.1080/17290376.2018.1527245.
The acceptability of lifelong antiretroviral therapy (ART) among HIV-positive women in high-burden Nigeria, is not well-known. We explored readiness of users and providers of prevention of mother-to-child transmission of HIV (PMTCT) services to accept lifelong ART -before Option B plus was implemented in Nigeria. We conducted 142 key informant interviews among 100 PMTCT users (25 pregnant-newly-diagnosed, 26 pregnant-in-care, 28 lost-to-follow-up (LTFU) and 21 postpartum women living with HIV) and 42 PMTCT providers in rural North-Central Nigeria. Qualitative data were manually analyzed via Grounded Theory. PMTCT users had mixed views about lifelong ART, strongly influenced by motivation to prevent infant HIV and by presence or absence of maternal illness. Newly-diagnosed women were most enthusiastic about lifelong ART, however postpartum and LTFU women expressed conditionalities for acceptance and adherence, including minimal ART side effects and potentially serious maternal illness. Providers corroborated user findings, identifying the postpartum period as problematic for lifelong ART acceptability/adherence. Option B plus scale-up in Nigeria will require proactively addressing PMTCT user fears about ART side effects, and continuous education on long-term maternal and infant benefits. Structural barriers such as the availability of trained providers, long clinic wait times and patient access to ART should also be addressed.
在艾滋病负担沉重的尼日利亚,HIV 阳性女性对终身抗逆转录病毒疗法(ART)的接受程度尚不清楚。在尼日利亚实施“B 方案加强版”之前,我们探讨了预防母婴传播 HIV(PMTCT)服务的使用者和提供者接受终身 ART 的意愿。我们在尼日利亚中北部农村地区对 100 名 PMTCT 使用者(25 名新诊断出怀孕的女性、26 名正在接受治疗的孕妇、28 名失访者以及 21 名感染 HIV 的产后女性)和 42 名 PMTCT 提供者进行了 142 次关键信息访谈。通过扎根理论对定性数据进行了人工分析。PMTCT 使用者对终身 ART 看法不一,这在很大程度上受到预防婴儿感染 HIV 的动机以及产妇是否患病的影响。新诊断出怀孕的女性对终身 ART 最为热情,然而产后女性和失访者对接受和坚持治疗提出了一些条件,包括 ART 的副作用要最小以及产妇可能患有严重疾病。提供者证实了使用者的调查结果,指出产后阶段在终身 ART 的可接受性/依从性方面存在问题。在尼日利亚扩大“B 方案加强版”的实施需要积极解决 PMTCT 使用者对 ART 副作用的担忧,并持续开展关于母婴长期益处的教育。还应解决一些结构性障碍,如训练有素的提供者的可获得性、诊所候诊时间长以及患者获取 ART 的途径等问题。